highlight earn call
new loan growth less rate sensit
food ppi re-acceler april trajectori remain encourag
ep line fine-tun estimate
growth acceler helium issu blow away
stronger execut turnaround progress
new cabinet new market continu drive growth
inject consensu impli bcfd tighten weather-
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report
singl factor make invest decis
zilucoplan remain track phase gmg trial track start
random double-blind placebo-control studi expect enrol subject
achr primari endpoint chang mg activ daili live mg-adl score
baselin week addit registr trial compani also track
initi trial second neuromuscular indic commenc studi
zilucoplan xr formul employ plga microspher sustain releas technolog
util sever commerci product us oral small molecul inhibitor
rarx life-cycl manag initi addit indic pursu may offer
option name could futur sourc upsid
recent gmg ole data show sustain activ subject initi random zilucoplan
mg/kg demonstr continu respons week week increment
reduct versu baselin qmg week week mg-adl
week week result statist signific clinic
meaning support thesi zilucoplan well posit potenti target
patient popul well beyond what current serv complement inhibitor encouragingli
patient switch placebo zilucoplan mg/kg week also saw clinic
meaning statist signific improv week
valuat reiter outperform rate tp updat model actual
adjust expens project model ep vs prior
compani cash cash equival expect abl fund opex
capital-expenditure least first quarter risk thesi includ clinic commerci
regulatori headwind
azedra launch steadili make headway report current treatment
request patient total activ center manag expect remain
center activ year end addit azedra revenu begin record
second quarter year compani continu dialogu fda initi
trial explor azedra addit mibg-avid tumor type lastli present lt
safeti data azedra june
psma pipelin progress compani enthusiast progress pyl
enrol pivot trial condor ahead schedul enrol enrol
complet expect data earli data present multipl investigator-initi
trial util pyl also encourag chang clinic manag occur
patient initi decis pivot trial
made base earli data trial
valuat reiter outperform rate tp updat model base
actual expect expens run rate ep vs old
compani cash cash equival risk thesi includ clinic regulatori
commerci headwind
highlight earn call
obseva provid increment clariti linzagolix uterin fibroid
endometriosi trial compani expect complet enrol uterin fibroid
primros studi quarter set result two uterin fibroid studi
primros primros compani plan file approv
uterin fibroid late meanwhil compani announc expect begin enrol
patient endometriosi edelweiss trial compani expect
patient popul endometriosi trial similar popul
primari endpoint co-primari endpoint look respond term
menstrual pain non-menstru pain studi power detect respons rate
treatment arm vs respons rate placebo arm use analges opioid
record taken account assess clinic meaning respons
increment thought uterin fibroid market opportun oral gnrh
receptor antagonist class compani believ higher unmet need endometriosi
rel uterin fibroid patient endometriosi constant pain current treatment
meet need patient uterin fibroid may accustom increas
blood flow symptom onset gradual suggest awar import off-set
compani believ access oral gnrh antagonist may better time launch
uterin fibroid rel endometriosi
in-lin earn minor model mainten updat model base run-rat
expens compani expect cash use oper
model ep vs old risk thesi includ clinic regulatori
commerci headwind
preliminari view brookfield asset manag bam report headlin ffo
beat view equal street came near top end
rang seri brookfield group member report strong
result date public lp per barrag beat result continu trend
balanc fund rais continu posit versu expect may concern
expect first close infrastructur fund continu growth client
posit howev would look enhanc oaktre acquisit creativ
compound credit posit platform
select detail notabl includ fee bear capit y-o-
public lp privat fund public
secur fee-rel earn quarter vs
major differ past brookfield busi partner perform fee ltm fre
vs realiz carri interest
vs third-parti core
liquid futur deploy
confer call bam result call may eastern access via
passcod
valuat target price sum fre free-rel earn asset
manag stub underli public lp appreci approxim current valu
risk target rate includ structur realiti public lp valu fund flow fee
stream tax chang
price month
new loan growth
region file focu guidanc updat loan growth
expect rais balanc sheet manag includ disclosur relat asset sensit
hedg strategi latter drive toward neutral credit qualiti migration/critic asset
trend estim target price unchang detail follow
guidanc point loan growth expect rais manag guid loan
growth low mid-singl digit previou guidanc low singl digit best tell
rais guidanc three week post april earn call tie sticki loan
growth year date still expect run somewhat alongsid health capit
market broad base healthi loan growth
disclos asset sensit decreas path neutral see detail sensit
hedg strategi target
credit qualiti migrat critic loan increas commerci
critic increas line peer group median critic increas excess
estim unchang per share
respect base case estim risk/sensit tie econom activ interest rate loan
demand deposit growth credit qualiti migrat cost competit valu scale
matur consolid industri
price month
happen bpmp report adj ebitda cse
in-lin street consensu adj dcf vs cse result
coverag strong onshor volum larg off-set weaker anticip
chang onshor volum beat cse driven volum vs cse
like benefit lower enb mainlin apportion last quarter manag
highlight higher apportion driver weaker volum aggreg off-shore
volum miss cse driven proteus/endymion post volum
cse like due larger anticip impact expect downtim first half
what import quiet quarter overal result larg in-lin view stronger
estim volum posit given manag seem talk expect
pipelin earn call expect volum remain mvc
throughout volum vs mvc given weaker
expect off-shore volum look addit commentari manag overal
outlook gulf mexico expect off-shore growth remain somewhat mute
new tie-in appomattox begin ramp
stock react expect fairli neutral reaction larg in-lin result
commentari call like focus manag long-term outlook gulf mexico
also look new commentari drop-down
price month
post ep fy guidanc unchang report adj ep
cse consensu adj ebitda slightli cse
translat margin cse result driven strong
perform refin servic broad base price off-set lower zeolyst jv result
custom order time well understood re-affirmed sale guidanc
ebitda guidanc guid
overal view today releas slight posit believ zeolyst headwind
well understood investor reaffirm guidanc bode well back half
strong refin servic result weigh catalyst order time refin servic saw
top-line grow due improv price renew contract regener
servic virgin sulfur acid busi catalyst sale decreas flat ex-fx zeolyst
jv sale result custom order time well anticip perform
materi revenu fell ex-fx back improv price/mix perform
chemic sale flat ex-fx better price/mix off-set weaker custom
demand consum product line total ebitda ex-fx
mainli due zeolyst order time catalyst ebitda yr/yr cost relat
restart capac pm partial off-set double-digit ebitda growth refin
servic strong price
question call updat organ growth invest portfolio ii
comment pick-up demand see advanc imo implement iii
updat thermodrop adopt think increment invest
thermodrop iv think price silica catalyst pm pc
 updat raw price trend plan off-set headwind
price month
ep line fine-tun estimate
ep beat consensu cah adj ep handili exceed
estim stronger revenu off-set weaker profit factor
line drive beat note narrow rais guidanc
midpoint fulli encompass sizeabl ep beat rais ep
reflect ep upsid partial off-set lower profit expect tp
stand
revenu ahead profit light medic woe ensu revenu
stronger core growth vs estimate medic
line view stronger volum partial off-set divestitur china
navihealth pharma segment oper profit growth exceed plan
medic profit growth significantli disappoint reflect increas
cost privat label product aforement divestitur ebitda margin fell
bp bp plan gener billion cash facilit million
share may move lower expect admittedli low meaning oper
miss driven weak medic segment perform medic oper profit
expect declin lsd-msd vs prior rise msd-hsd view share may eas
said encourag stronger pharma experi importantli announc
renew relationship june underscor valu provid
partner continu transit year on-going profit pressur
across pharma medic segment expos prolong challeng diversif
strategi focu call like remain medic profit trajectori pharmaceut growth
driver opioid litig portfolio optim risk drug price acquisit
price month
growth acceler helium issu
rel line number posit develop
includ secur better suppli helium major drag year embark store
optim initi believ posit implic sale ebitda look
believ support return stronger growth late year
comp line set better comp remain messi although
adj transitori element incl helium calendar shift comp acceler
headlin improv base estimate bp weather
although helium expect remain headwind benefit improv suppli
well stronger licens product halloween time
helium still expect headwind new suppli contract support
improv compani discuss similar impact bp
start abat august lap headwind last year new suppli
contract start also plan price increas off-set higher commod
encourag store close announc given lacklust retail comp recent year
encourag announc clean consolid market
drive higher comp remain store market well higher ebitda
believ strategi support uniqu offer grow on-line busi
pick store
price month
adjust estim guidanc updat model guidanc perform
forecast ep vs guidanc although see potenti
stronger growth well consensu headwind year ease/
benefit initi ramp tp goe equat ebitda
stronger execut turnaround
rais ep estim keep ep
target price unchang bung ep beat estim wide
margin larg due phase result rather stronger condit market
manag warn slightli weaker impact last year
mtm gain continu revers food ingredi divis experi higher
cost addit manag maintain outlook year due declin crush
margin discount futur curv uncertainti relat s-china trade relationship
substanti contract chines pig herd relat asf maintain outperform
rate due view newli constitut board gener sharehold valu
slim portfolio improv execut possibl sell busi
valuat target price reflect estim fundament earn
power compani addit probabl takeout estim
fundament valu assum ep power price-to-earnings multipl in-lin
multipl assum long term earn power inabl fetch premium bung
asset strateg buyer repres biggest risk target price
price month
new cabinet new market continu
drive growth
remain outperform report solid ebitda y/i ahead
consensu revenu y/i consensu impli slightli better
margin guidanc reiter impli organ ebitda growth expect
given visibl agss busi product momentum think guidanc
achiev sale y/i expect modest share
gain remain outperform
what import egm ebitda ahead street ship
consensu lumpi quarter quarter leverag increas
adjust integr acquisit manag maintain ntm leverag target
chang asp mostli premium orion sale ebitda
capital-expenditure guidanc maintain sever weather impact domest revenu per day
manag expect revenu per day recov throughout year
chang estim updat model reflect actual ebitda
increas slightli within agss rang ep
higher share count tp unchang
risk game technolog highli competit market maintain product perform
market share gain depend key personnel product replac cycl custom
concentr sensit end market us consum
price month
conclus person commerci line result appear remain wed
estim target level order attain consist high-singl low-doubl digit return
impli liberti mutual publicli trade continu seek increment rate
portfolio action improv profit detail
core roe compar incom
underli combin ratio improv y/i half due expens ratio
improv all-in combin ratio y/i
auto price flattish q/q y/i
pif growth neg flattish q/q retent histor level
price flattish q/q y/i
pif growth neg flattish q/q y/i retent
underli combin ratio improv y/i larg due expens ratio
improv all-in combin ratio y/i
specialti commerci vs q/q y/i
reinsur vs q/q y/i
domest comml flattish q/q slightli y/i
recent commentari also announc two transact aim optim insur
portfolio first agreement purchas global sureti credit reinsur oper
amtrust solidifi market lead posit sureti second sale pembrok
syndic ironshor europ busi elimin duplic effort therebi streamlin
inject consensu impli
bcfd tighten weather-adjust
storag inject consensu work ga storag increas bcf week
end may slightli consensu bcf midpoint bcf forecast
rang last week inject compar year-ago week bcf five-year averag
bcf inject inventori increas bcf narrow surplu vs last year
bcf narrow deficit vs five-year averag bcf
weather last week colder last year averag last week weather
colder year-ago week averag respect sinc
septemb weather colder last year averag
respect hdd remain ahead us heat season
last week inject impli weather-adjust s/d balanc tighten bcfd
last month estim weather-adjust s/d oversuppli
bcfd vs last year five-year averag storag exit winter
bcf averag project storag build novemb
bcf surplu year ago level averag
forecast bcf inject next week forecast bcf inject
report next week compar year-ago week bcf five-year averag
modestli attract vs long-dat futur curv
normal forecast top pick eca
vnom top ga pick
happen report adj ebitda beat cse
consensu dcf cse cqp
ebitda cse consensu capit return plan
announc surpris possibl import reiter
what import volum came expect cargo spl in-lin cse
cargo cse overal saw tbtu commiss volum
recogn quarter in-lin cse tbtu thu see rel clean
compar number commiss cargo creat account nois
reduct capit spend quarter addit ebitda result suggest better-
than-expect price realiz speak lng strong contract book rel low
spot price exposur boost confid stori
chang jkm averag
guidanc first given investor concern increas would
walk back expect reiter guidanc adj ebitda
dcf cqp reiter dpu guidanc spl
reach substanti complet start commerci oper februari march
respect next key oper updat still track
commiss train began januari still schedul ferc
side note previous disclos ea ph march midship notic proceed
stock react expect posit reaction beat guidanc
reiter possibl mute somewhat disappoint earli releas lng capit
alloc plan given continu expect management announc plan soon
maintain financi flexibl growth option appear top goal see
dividend like initi end year cash flow continu ramp train enter
commerci servic call look guidanc well updat spl
fid like next month ph
week host meet bhge esv conjunct
off-shore technolog confer houston pleas reach team like
anoth onshore-focus over-the-counter fourth year over-the-counter confer focus
onshor oppos off-shore though int market outperform nam featur
promin highlight select takeaway note bodi find summari key
takeaway meet organ compani
limit visibl nam servic demand common theme servic
demand opac visibl beyond limit instanc visibl
outlook slow bleed coincid team view
capital-expenditure spent q/q declin throughout year detriment rig
complet
disciplin respons grow investor concern languish of declin
flattish exclud goodwill/intang past three
year heard reiter commit remain disciplin respect capital-expenditure
say ad singl frac fleet say capital-expenditure budget go
toward area tight servic capac presum see better pricing/margins/
conclud complet earn scorecard earn scorecard summar
compani result vs credit suiss estim consensu ep ebitda cfp
capital-expenditure net debt product cost aisc identifi guidanc revis
 ep production/cost await goldcorp guidanc
auy ep slight vs cerro moro continu perform
ego ep miss driven time sale
iag earn wrap westwood risk lower tp
hbm ep in-lin consensu pampacancha delay trim tp
food ppi re-acceler april trajectori
finish consum food ppi total acceler bp sequenti
march trend larg driven big swing typic volatil crude categori
april vs march within finish consum food reason proxi
overal food inflat process sub-categori also improv bp sequenti
march stack highest level sinc
septemb ltm averag remain near flat food manufactur ppi also
acceler bp sequenti march keep measur posit
territori inflect novemb stack improv vs last
month ltm averag flat
present food ppi data major product categori figur figur
april fresh dri veget dairi meat categori acceler fresh dri
veget y/i continu experi high level inflat like due shortag
certain product dairi y/i sit solidli inflationari territori experienc
deflat much trend consist foodservic distribut
compani comment week highlight inflat produc dairi center-of-
plate item cite inflat fruit cereal/bakeri categori stabilized/deceler
recent month fruit berri y/i revers multi-month trend inflat
earn call last week call like better summer grow season
cpi data month april releas tomorrow may remind march food
cpi acceler yoy growth come februari
februari first time food cpi exceed sinc april
encourag continu trend ltm averag remain
stack improv modestli note figur trend may
partial attribut price spike certain product evid ppi back dec-jan
convers truck ceo regul steer tenur driver away
opportun speak tenur ceo privat truck compani truck
main take-away corrobor previou comment troubl line best
safest driver industri upset regul have/stil leav industri
less stress posit continu increas pool younger/less experienc driver
industri prolong tight labor market end sight season driver
primarili upset state feder complianc statu treat
someon first trip even veteran perfect drive record would
bring better driver back view combin addit freedoms/
lenienc grant driver clean record weaker economi provid
commerci auto profit still year away conclus commerci auto loss-
expens inflat level run mid- high-single-digit level rel price
level impli take year troubl line busi return profit
packag writer cb etc
charl martineau univers toronto compani mention price
